Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Reimbursement
Pharma
BioMarin downsizes gene therapy efforts to focus on 3 markets
After previously floating the possibility of divesting Roctavian, BioMarin decided to keep the hemophilia A gene therapy—but with a narrowed focus.
Angus Liu
Aug 6, 2024 10:34am
Bluebird pushes Lyfgenia's US coverage to nearly 200M people
Jan 4, 2024 11:15am
Bluebird signs first coverage deal for SCD gene therapy Lyfgenia
Dec 14, 2023 11:04am
Is the cost of Vertex's Trikafta hampering CF treatment?
Feb 14, 2022 11:46am
Medicare received majority of comments iffy on Biogen's Aduhelm
Feb 1, 2022 11:34am
Biogen wants Aduhelm supporters to make their voices heard
Jan 13, 2022 11:13am
